CCK4-induced panic in healthy subjects II: Neurochemical correlates

European Neuropsychopharmacology

Volumn 9, Issue 1-2, 1999, Pages 157-164

  Jerabek, Ilona ^a,c   Boulenger, Jean Philippe ^a   Bradwejn, Jacques ^b   Drumheller, Andrea ^a   Lavallée, Yvon Jacques ^a   Jolicoeur, François B ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Blood platelet; Catecholamines; Cholecystokinin tetrapeptide; Healthy subjects; Panic; Plasma

Indexed keywords

ADRENALIN; CATECHOLAMINE; DOPAMINE; NORADRENALIN; TETRAGASTRIN;

ADRENALIN BLOOD LEVEL; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROCHEMISTRY; NORADRENALIN BLOOD LEVEL; NORMAL HUMAN; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; TISSUE LEVEL; ADULT; BLOOD; CHEMICALLY INDUCED DISORDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM;

ADULT; BLOOD PLATELETS; CATECHOLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOPAMINE; DOUBLE-BLIND METHOD; EPINEPHRINE; FEMALE; HUMANS; MALE; NOREPINEPHRINE; PANIC DISORDER; TETRAGASTRIN;

EID: 0032587049     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(98)00021-2     Document Type: Article

References (72)

1. Albus, M., Zahn, T.P., Breier, A., 1992. Anxiogenic properties of yohimbine. I. Behavioral and biochemical measures. Eur. Arch. Psychiatry Clin. Neurosci. 241, 337-344.
2. Appleby, I.L., Klein, D.F., Sachar, E.J., Levitt, M., 1981. Biochemical indices of lactate-induced panic: A preliminary report. In: Klein, D.F., Rabkin, J. (Eds.), Anxiety: New Research and Changing Concepts. Raven Press, New York, pp. 411-423.
3. Besses, G.S., Burrow, G.N., Spaulding, S.W., Donabedian, R.K., Pechinski, T., 1975. Dopamine infusion acutely inhibits TSH and prolactin response to TRH. J. Clin. Endocrinol. Metab. 41, 985-988.
4. Boulenger, J.P., Marangos, P.J., Zander, K.J., Hanson, J., 1986. Stress and caffeine: Effects on central adenosine receptors. Clin. Neuropharmacol. 9, 79-83.
5. Boulenger, J.P., Uhde, T.W., Wolf, III E.A., Post, R.M., 1984. Increased sensitivity to caffeine in patients with panic disorders. Arch. Gen. Psychiatry 41, 1067-1071.
6. Boulenger, J.P., Zarifian, E., 1987. L'approche biologique de la pathologie anxieuse. In: Boulenger, J.P. (Ed.), L'Attaque de Panique: Un Nouveau Concept? J.P. Goureau, Château du Loi, pp. 119-151.
7. 2-induced panic attacks with cholecystokinin-induced panic attacks in panic disorder patients. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 15, 237-239.
8. Bradwejn, J., Koszycki, D., 1994. The cholecystokinin hypothesis of anxiety and panic disorder. Ann. New York Acad. Sci. 713, 273-282.
9. Bradwejn, J., Koszycki, D., 1994. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am. J. Psychiatry 151, 261-263.
10. Bradwejn, J., Koszycki, D., Annable, L., Couëtoux du Tertre, A., Reines, S., Karkanias, C., 1992. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. Biol. Psychiatry 32, 903-912.
11. Bradwejn, J., Koszycki, D., Bourin, M., 1991. Dose ranging study of the effects of cholecystokinin in healthy volunteers. J. Psychiatry Neurosci. 16, 91-95.
12. Bradwejn, J., Koszycki, D., Meterissian, G., 1990. Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can. J. Psychiatry 35, 83-85.
13. Bradwejn, J., Koszycki, D., Payeur, R., Bourin, M., Borthwick, H., 1992. Replication of action of cholecystokinin tetrapeptide in panic disorder: Clinical and behavioral findings. Am. J. Psychiatry 149, 962-964.
14. Bradwejn, J., Koszycki, D., Shriqui, C., 1991. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Arch. Gen. Psychiatry 48, 603-610.
15. Braune, S., Albus, M., Frohler, M., Hohn, T., Scheibe, G., 1994. Psychological and biochemical changes in patients with panic attacks in a defined situational arousal. Eur. Arch. Psychiatry Clin. Neurosci. 244, 86-92.
16. Brodie, M.S., Dunwiddie, T.V., 1987. Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro. Brain Res. 425, 106-113.
17. Butler, J., O'Halloran, A., Leonard, B.E., 1992. The Galway study of panic disorder. II: Changes in some peripheral markers of noradrenergic and serotonergic function in DSM III-R panic disorder. J. Affect. Disord. 26, 89-99.
18. Cameron, O.G., Gunsher, S., Hariharan, M., 1990. Venous plasma epinephrine levels and the symptoms of stress. Psychomotor Med. 52, 411-424.
19. 2-adrenergic receptor binding and plasma catecholamines: Before and during imipramine treatment in patients with panic anxiety. Arch. Gen. Psychiatry 41, 1144-1148.
20. Cameron, O.G., Smith, C.B., Lee, M.A., Hollingworth, P.J., Hill, E.M., Curtis, G.C., 1990. Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol. Psychiatry 28, 3-20.
21. Carr, D.B., Sheehan, D.V., Surmann, O.S., et al., 1986. Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am. J. Psychiatry 143, 483-494.
22. Carstensen, E., Yudkin, J.S., 1994. Platelet catecholamine concentrations after short-term stress in normal subjects. Clin. Sci. 86, 35-41.
23. Chamberlain, K.G., Pestell, R.G., Best, J.D., 1990. Platelet catecholamine contents are cumulative indexes of sympathoadrenal activity. Am. J. Physiol. 259, E141-E147.
24. Charney, D.S., Galloway, M.P., Heninger, G.R., 1984. The effects of caffeine on plasma MHPG, subjective anxiety, autonomie symptoms and blood pressure in healthy humans. Life Sci. 35, 135-144.
25. Charney, D.S., Heninger, G.R., Breier, A., 1984. Noradrenergic function in panic anxiety: Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry 41, 751-763.
26. Charney, D.S., Heninger, G.R., Jatlow, P.I., 1985. Increased anxiogenic effects of caffeine in panic disorders. Arch. Gen. Psychiatry 42, 233-243.
27. Charney, D.S., Woods, S.W., Price, L.H., Goodman, W.K., Glazer, W.M., Heninger, G.R., 1990. Noradrenergic dysregulation in panic disorder. In: Ballenger J.C. (Ed.), Neurobiology of Panic Disorder. Wiley-Liss, New York, pp. 91-105.
28. Crawley, J.N., 1991. Cholecystokinin-dopamine interactions. Trends Pharmacol. Sci. 12, 232-236.
29. Csonka, E., Fekete, M., Nagy, G., Szanto-Fekete, M., Feledgy, G., Penke, B., Kovaks, K., 1988. Anxiogenic effects of cholecystokinin in rats. In: Penke, B., Torok, A. (Eds.), Peptides. Walter de Gruyter and Co., New York.
30. D'Andrea, G., Welch, K.M.A., Grunfeld, S., Joseph, R., Nagel-Leiby, S., Cananzi, A.R., 1989. Platelet free catecholamines in healthy women. Thrombosis Res. 55, 165-168.
31. de Montigny, C., 1989. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiatry 46, 511-517.
32. 2-36. Neuropeptides 27, 291-296.
33. Fuxe, K., Agnati, L.F., Van der Haeghen, J.J., et al., 1985. Cholecystokinin neuron systems and their interactions with the pre-synaptic features of the dopamine neuron systems. A morphometric and neurochemical analysis involving studies on the action of cholecystokinin-8 and cholecystokinin-58. Ann. New York Acad. Sci. 448, 231-254.
34. Goldstein, D.S., Keiser, H.R., 1985. Neural circulatory control in the hyperdynamic circulatory state syndrome. Am. Heart J. 109, 387-390.
35. Gorman, J.M., Liebowitz, M.R., Fyer, A.J., et al., 1985. Platelet monoamine oxidase activity in patients with panic disorder. Biol. Psychiatry 20, 852-857.
36. Gorman, J.M., Leibowitz, M.R., Fyer, A.J., Stein, J., 1989. A neuroanatomical hypothesis for panic disorder. Am. J. Psychiatry 146, 148-161.
37. Gurguis, G.N.M., Uhde, T.W., 1991. Anxiety Disorders: A review of neurotransmitter systems and new directions in research. In: Walker, J.R., Norton, R.G., Colin, R.A. (Eds.), Panic Disorder and Agoraphobia: A Comprehensive Guide for the Practitioner. Brooks/ Cole Publishing Company, Pacific Grove, CA, pp. 433-469.
38. Guttenmacher, L.B., Murphy, D.L., Insel, T.R., 1983. Pharmacologic models of anxiety. Compr. Psychiatry 24, 312-326.
39. Harro, J., Vasar, E., Bradwejn, J., 1993. CCK in animal and human research on anxiety. Trends Pharmacol. Sci. 14, 244-249.
40. Hokfelt, T., Skirboll, L., Everitt, B., et al., 1985. Distribution of cholecystokinin-like immunoreactivity in the nervous system. Co-existence with classical neurotransmitters and other neuropeptides. Ann. New York Acad. Sci. 448, 255-274.
41. 4-induced panic in healthy subjects I: psychological and cardiovascular effects, European Neuropsychopharmacology 9, 149-155.
42. Joborn, H., Hjemdahl, P., Larsson, P.T., et al., 1990. Chest 97, 1098-1105.
43. Ko, G.N., Elsworth, J.D., Roth, R.H., Rifkin, B.G., Leigh, H., Redmond, D.E., 1983. Panic-induced elevation of plasma MHPG levels in phobic-anxious patients. Arch. Gen. Psychiatry 40, 425-430.
44. Kopin, I.J., 1995. Definition of stress and sympathetic neronal responses. Ann. New York Acad. Sci. 771, 19-30.
45. Koszycki, D., Bradwejn, J., Bourin, M., 1991. Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in healthy volunteers. Eur. Neuropsychopharmacol. 1, 137-141.
46. Koszycki, D., Cox, B.J., Bradwejn, J., 1993. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am. J. Psychiatry 150, 1881-1883.
47. Kvetnansky, R., Pacak, K., Fukuhara, K., et al., 1995. Sympathoadrenal system in stress. Interaction with hypothalamic-pituitary-adrenocortical system. Ann. New York Acad. Sci. 771, 131-158.
48. 4 induced panic symptoms. Neuropsychopharmacology, XXth Meeting of the CINP, Melbourne, Australia, June 1996.
49. Liebowitz, M.R., Fyer, A.J., German, J.M., Dillon, D.J., Appleby, I.L., Levy, G.A., 1984. Lactate provocation of panic attacks. Arch. Gen. Psychiatry 41, 764-770.
50. Liebowitz, M.R., Gorman, J.M., Fyer, A., Dillon, D., Levitt, M., Klein, D., 1986. Possible mechanisms for lactate's induction of panic. Am. J. Psychiatry 143, 495-502.
51. Liebowitz, M.R., Gorman, J.M., Fyer, A., 1985. Lactate provocation of panic attacks II: Biochemical and physiological findings. Arch. Gen. Psychiatry 42, 709-719.
52. Merkel, A.D., Barbeau, A., 1982. Plasma catecholamines in Friedreich's ataxia assayed using high performance liquid chromatography with electrochemical detection. Can. J. Neurol. Sci. 9, 205-208.
53. Mielke, K., Strobel, G., 1994. The potential of intact human platelets for sulfoconjugation of norepinephrine in vitro. Life Sci. 55, 1657-1663.
54. Nesse, R.M., Cameron, O.G., Buda, A.J., McCann, D.S., Curtis, G.C., Huber-Smith, M.J., 1985. Urinary catecholamines and mitral valve prolapse in panic-anxiety patients. Psychiatry res. 14, 67-75.
55. Nesse, R.M., Curtis, G.C., Thyer, B.A., McCann, D.S., Huber-Smith, M.J., Knopf, R.F., 1985. Endocrine and cardiovascular response during phobic anxiety. Psychosom. Med. 47, 320-332.
56. Pitchot, W., Ansseau, M., Gonzalez Moreno, A., Hansenne, M., von Frenckell, R., 1992. Dopaminergic function in panic disorder: Comparison with major and minor depression. Biol. Psychiatry 32, 1004-1011.
57. Pohl, R., Yeragani, V., Balon, R., Ortiz, A., Aleem, A., 1990. Isoproterenol-induced panic: A beta-adrenergic model of panic anxiety. In: Ballenger, J.C. (Ed.), Neurobiology of Panic Disorder. Wiley-Liss, New York, pp. 107-120.
58. Ratge, D., Kohse, K.P., Steedmüller, U., Wisser, H., 1991. Distribution of free and conjugated catecholamines between plasma, platelets and erythrocytes: different effects of intravenous and oral catecholamine administrations. J. Pharmacol. Exp. Ther. 257, 232-238.
59. Robertson, D., Frolick, J.C., Carr, R.K., et al., 1978. Effects of caffeine on plasma renin activity, catecholamines and blood pressure. New Engl. J. Med. 298, 181-185.
60. Robertson, D., Wade, D., Workman, R., Woosley, R.L., Oates, J.A., 1981. Tolerance to the humoral and hemodynamic effects of caffeine in man. J. Clin. Invest. 67, 1111-1117.
61. Roy-Byrne, P.P., Uhde, T.W., Post, R.M., Gallucci, W., Chrousos, G.H., Gold, P.W., 1986. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am. J. Psychiatry 143, 896-899.
62. Roy-Byrne, P.P., Uhde, T.W., Sack, D., Linnoila, M., Post, R.M., 1986. Plasma HVA and anxiety in patients with panic disorder. Biol. Psychiatry 21, 849-853.
63. Schneider, P., Evans, L., Ross-Lee, L., et al., 1987. Plasma biogenic amine levels in agoraphobia with panic attacks. Pharmacopsychiatry 20, 102-104.
64. Smith, C.C.T., Curtis, L.D., Delamothe, A.P., Prichard, B.N.C., Betteridge, D.J., 1985. The distribution of catecholamines between platelets and plasma in normal human subjects. Clin. Sci. 69, 1-6.
65. Smith, C.C.T., Prichard, B.N.C., Betteridge, D.J., 1992. Plasma and platelet free catecholamine concentrations in patients with familial hypercholesterolaemia. Clin. Sci. 82, 113-116.
66. Snyder, S.H., Sklar, P., 1984. Behavior and molecular actions of caffeine: Focus on adenosine. J. Psychiatric Res. 18, 91-106.
67. Uhde, T.W., Siever, L.J., Post, R.M., Jimerson, D.C., Boulenger, J.P., Buchsbaum, M.S., 1982. The relationship of plasma free MHPG to anxiety and psycho-physical pain in normal volunteers. Psychopharmacol. Bull. 18, 129-132.
68. Van den Hout, M.A., Griez, E., 1984. Panic symptoms after inhalation of carbon dioxide. Br. J. Psychiatry 144, 503-507.
69. Villacres, E.C., Hollifield, M., Katon, W.J., Wilkinson, C.W., Veith, R.C., 1987. Sympathetic nervous system activity in panic disorder. Psychiatry Res. 21, 313-321.
70. Winer, B.J., 1971. Statistical Principles in Experimental Design. McGraw-Hill, New York, p.384.
71. Wyatt, R.J., Portnoy, B., Kupfer, D.J., Snyder, F., Engelman, K., 1971. Resting catecholamine concentrations in patients with depression and anxiety. Arch. Gen. Psychiatry 24, 65-70.
72. Yu, P.H., Bowen, R., Carlson, K., O'Sullivan, K., Boulton, A.A., 1982. Comparison of biochemical properties of platelet monoamine oxidase in mentally disordered and healthy individuals. Psychiatry Res. 6, 107-121.